BioVie Inc Stock News

BioVie Inc. - Special Call Company Participants Cuong Viet Do - President, CEO & Director Conference Call Participants Craig Brelsford Presentation Craig Brelsford Hello. This is Craig Brelsford with RedChip Companies.

CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025.

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit con...

Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging

Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission

Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation

CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial ...